With the surging demand for biologics and biosimilars – such as GLP1 therapies – there is a pressing need for fast-turnaround, flexible and cost-effective drug delivery solutions. PDA – Parenteral Drug Association Vienna, was a great place for having in-depth conversations with all stakeholders in this complex landscape from pharma to platform companies and to be a part of the solutions in this evolving sector.

Auto Injectors and Drug Delivery

Large volume auto injectors are a hot topic, one that requires re-evaluating the traditional perception of patient comfort. Extended delivery times – once considered a barrier – are now acceptable for many patients, paving the way for a move from on-body drug delivery to an auto-injector based solution in many cases. Read our article on Developing Auto-Injectors: Designing for Small and Large Volume Drug Delivery

Platform vs Bespoke Drug Delivery Development

There is a clear tendency towards using device solutions offered by platform companies. However the complexity of the approval process for combination products is posing a significant challenge to the perceived ubiquity of platform devices. Also the flexibility required in supply chain and device features naturally adds to the costs and risks associated with such solutions. On the other hand developing a bespoke device is not always commercially viable for many new drugs, especially some orphan drugs or for smaller niche pharma companies. There is no perfect solution other than collaborative approaches and risk-mitigated compromises. Read our article on Platform vs Bespoke Drug Delivery Development: Strategic Choices for Effective Combination Products

Simulation and Modelling in Drug Delivery Development

Simulation and Modelling is a key tool for evaluating various aspects of combination products from design to performance, an approach that significantly reduces cost, time scale and risks to the programme. Read our article on Accelerating Medical Device Verification with Digital Twin Technology

Dr Ash Ghadar CEO Haughton Design Dr Ash Ghadar Chief Executive Officer

Get in Touch with Dr Ash Ghadar

Ash brings over 25 years of experience in leadership, board advisory roles and hands-on development within the health tech and medical device sectors. He has successfully guided numerous national and international companies through the complete product lifecycle from ideation to full-scale commercialisation and scale-up.

Get In Touch

Related content

Latest Posts

Haughton Design Appoints new CEO Press Release

Read More...

Inside a Sustainable Inhaler: Does reusable mean better?

Read More...

Share

Haughton Design
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.